Teva is the leading generics company in America, with $8.8 billion sales in 2011. Headquarters are in North Wales, Pennsylvania, Teva Americas has more than 12,000 employees in 13 US states, the District of Columbia, Canada and Puerto Rico. Over 1.5 million Teva prescriptions are written each day in the US alone, 1,052 prescriptions per minute, while 1 out of every 7 generic prescriptions in the US and Canada is filled with Teva product.
Teva Asia is based at Teva headquarters in Israel, with representatives across the region, overseeing all aspects of the regional activity including marketing, registration logistics and distribution. Teva Asia supports Teva's strategic objectives and continuous global expansion. Teva Asia is responsible of commercial & sales activities in Japan, China, India and other countries across Asia.
EMIA is a division within Teva, coordinating all commercial activities in Eastern Europe, Israel, the Middle East and Africa. Headquartered in Israel, EMIA's representatives are positioned across the region, overseeing all activities, including marketing, registration, logistics and distribution. EMIA's people are committed to maintain fruitful, ongoing relationships with local communities and to achieve sustained profitable growth in each market.
Teva is the leading generics company in Europe, with $5.7 billion sales in 2011. Headquartered in the Netherlands, Teva Europe specializes in the development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biosimilars and Active Pharmaceutical Ingredients (APIs). Teva Europe has 14,000 employees in 29 European Union member states, plus Norway and Switzerland. About 1,186 doses of Teva medicine are taken by patients in Europe every second.